Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Episodic Migraine - the EVOLVE-2 Study

Next Previous
Trial Profile

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Episodic Migraine - the EVOLVE-2 Study

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 01 Dec 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Galcanezumab (Primary)
  • Indications Migraine
  • Focus Registrational; Therapeutic Use
  • Acronyms EVOLVE-2
  • Sponsors Eli Lilly and Company

Most Recent Events

  • 28 Nov 2023 Results of pooled post hoc analysis (n=462 from studies EVOLVE-1 and EVOLVE-2) assessing Effect of galcanezumab in women with episodic migraine meeting criteria for menstrually related migraine published in the Headache
  • 03 May 2023 Results of post hoc analysis (n=3348) assessing at population and individual patient levels, the sustained response of reduction in migraine headache days in patients with migraine treated with galcanezumab from two 6-month episodic migraine (EM; EVOLVE-1/EVOLVE-2), one 3-month chronic migraine (CM; REGAIN), and one 3-month treatment-resistant migraine (CONQUER) studies, published in the Headache.
  • 27 Apr 2023 Results of pooled analysis(n=1551 from 3 studies EVOLVE-1, EVOLVE-2, and CONQUER ) assessing Clinically meaningful improvement in disability (MIDAS score) in the absence of greater than 50% reductions in monthly migraine days with galcanezumab presented at the 75th Annual Meeting of the American Academy of Neurology 2023

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top